aldose reductase

Aldose reductase-IN-1 (AT-001) is a aldose reductase inhibitor (IC50: 28.9 pM).

Aldose reductase-IN-4 (compound IIc) is an inhibitor of aldose reductase with IC50 values of 11.70 μM for ALR1 and 0.98 μM for ALR2, respectively [1].

Aldose reductase-IN-5 is an inhibitor of aldose reductase (ALR2) that enhances the combination of inhibitory excitability and antioxidant capacity, thereby delaying the diabetes complications progress.

Aldose reductase-IN-3 (Compound 5) is an effective and moderately selective aldose reductase (AR) inhibitor (IC50=3.99 μM) with research potential in sepsis, a molecular target involved in various inflammatory diseases (including sepsis).

Aldose reductase-IN-6 (Compound 3) is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki of 0.018 μM. Notably, Aldose reductase-IN-6 demonstrates no cytotoxicity toward normal cells [1].

Aldose reductase-IN-2 (Compound 5f) is a potent aldose reductase (AR) inhibitor with antioxidant properties, making it a promising drug for anti-diabetic complications.

Isoliquiritigenin (ISL) is a flavonoid natural product that inhibits influenza virus replication (EC50=24.7 μM) and aldose reductase activity (IC50=320 nM). Isoliquiritigenin has antitumor activity.

2-Chloro-1-(4-fluorobenzyl)benzimidazole is an inhibitor of aldose reductase (ALR2).

Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.

oxepinac is an effective and well-tolerated compound for the treatment of painful osteoarthritis. oxepinac has no teratogenic effect on mouse and rabbit fetuses in animal experiments.

Alconil (Al 1567) is an aldose reductase inhibitor that may be used to study chronic obstructive pulmonary disease (COPD) and diabetes.

IDD388 is a selective and potent aldose reductase (ALR2) inhibitor with antitumor activity that inhibits the ALR1 receptor.

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

Sulindac sulfide (cis-Sulindac sulfide) is a non-steroidal anti-inflammatory compound that has a high affinity for COX-1 and acts as an inhibitor in Ras activation of Raf-1. Sulindac sulfide is a non-competitive inhibitor of gamma-secretase with an IC50 value of 20.2 μM. It is an active metabolite of sulinic acid.

Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts. Lidorestat can be used to treat complications of chronic diabetes.

Tolrestat (AY-27773) is a potent inhibitor of aldose reductase (IC50 = 35 nM).

1. Engeletin (Dihydrokaempferol 3-rhamnoside) may serve as a potential anti-inflammatory agent. 2. Engeletin possesses potent inhibition of PGE2 release with IC5 values of 19.6 μg/ml. 3. Engeletin inhibits a recombinant human aldose reductase (IC5 value=1.16 microM).

Ganoderenic acid A has a potent hepatoprotective, and cytotoxic effects, it shows inhibitory activity on human aldose reductase in vitro.

3-Isomangostin is a potent human aldose reductase inhibitor with an IC50 of 3.48 uM; it is also an acetylcholinesterase selective inhibitor. 3-Isomangostin has free radical scavenging activity; it shows antiplasmodial activity with IC50 values in the rang

Groenlandicine is a protoberberine alkaloid from Coptidis Rhizoma. Groenlandicine exhibits moderate inhibitory effect with IC50 value of 154.2 μM for human recombinant aldose reductase (HRAR). Groenlandicine selectively induces topoisomerase I-mediated DN

Imirestat (HOE 843) is an aldose reductase inhibitor that can be used in diabetes research.

Alrestatin (AY-22284) is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in vitro.

Ponalrestat is an aldose reductase inhibitor.

Ganoderic acid C2 has anti-inflammatory,and anti-tumor-promoting activities. Ganoderic acid C2 can inhibit histamine release, it also has inhibitory effects on the induction of Epstein-Barr Virus early antigen.

Gigantol is a novel inhibitor of the Wnt/β-catenin pathway. It inhibits Wnt/β-catenin signaling through downregulation of phosphorylated LRP6 and cytosolic β-catenin in breast cancer cells. Gigantol may be developed as a promising neuroprotective agent for successful MSC transplantation in ischemic diseases, it shows the protective effect against hydrogen peroxide-induced apoptosis in rat bone marrow mesenchymal stem cells through the PI3K/Akt pathway.Gigantol inhibits aldose reductase gene to exert its anti-cataract activity. Gigantol induces growth inhibition and apoptosis of HepG2 cells via the PI3K/Akt/NF-κB signaling pathway.Gigantol also shows α-glucosidase inhibitory activity.

EBPC is an inhibitor of aldose reductase.

Neosmitilbin (Neoastilbin) may have antioxidant and anti-inflammatory activities, it shows potent inhibition of lens aldose reductase.

Tectoridin (Shekanin) possesses an estrogenic and thyroid hormone-like agent by activating estrogen and thyroid hormone receptors. Tectoridin has anti-oxidant, anti-inflammatory and hypoglycemic activities; Tectoridin and its five metabolites inhibits the activities of lens aldose reductase in rat (IC : 1.4-15.5 μM).

Apigenin-7-glucuronide (Apigenin 7-O-glucuronide) possesses multiple activities, including antioxidant, anti-inflammatory, and aldose reductase inhibitory activities, it can inhibit MMP activities (IC50s: 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively).

Sulindac sulfone is a metabolite of the nonsteroidal anti-inflammatory drug sulindac.

APPA, an aldose reductase inhibitor, demonstrates efficacy in preventing apoptosis and symptoms of Streptozotocin-induced diabetes in rats through inhibition of the polyol pathway. This compound shows promise for research into diabetic nephropathy (DN) [1].

6-Hydroxyluteolin (Compound 17), a flavonoid, exhibits inhibition of aldose reductase (AR) [1].

Sorbinil is an Aldose reductase inhibitor. Sorbinil plays a therapeutic role in treating diabetes and diabetic complications decreases AR activity and inhibit the polyol pathway.

Dehydroglyasperin D exhibits anticancer, anti-inflammatory, anti-obesity, antioxidant and anti-aldose reductase effects, it inhibits the proliferation of HT-29 human colorectal cancer cells through direct interaction with phosphatidylinositol 3-kinase; it also mediates suppression of both COX-2 expression and the MLK3 signalling pathway through direct binding and inhibition of MLK3. Dehydroglyasperin D shows strong ferric reducing activities and effectively scavenged DPPH, ABTS(+), and singlet oxygen radicals.

Triptocalline A, a compound from Salacia chinensis, inhibits rat lens aldose reductase.

WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.WJ-39 inhibits oxidative stress and inhibits the activation of the inflammatory vesicle of the oligomerization structural domain-like receptor family, pyrin structural domain 3 (NLRP3).

Ganoderic acid Df, a lanostane-type triterpenoid isolated from the fruiting body of Ganoderma lucidum, potently inhibits aldose reductase with an IC 50 of 22.8 ± 0.6 μM [1].

Lidorestat monohydrate is an aldose reductase inhibitor potentially for the treatment of diabetic neuropathy and diabetic complications.

WF 2421 is an aldose reductase inhibitor produced by Humicola grisea.

Lucidumol A has relatively good effect against aldose reductase with IC50 of 19.1uM. Lucidumol A has cytotoxic activity, it reduced cell growth in three human carcinoma cells (Caco-2, HepG2, and HeLa cells) dose dependently with LC50s from 20.87 to 84.36

2'-Acetylacteoside has antioxidative activity. It can significantly attenuate glutamate-induced neurotoxicity at concentrations ranging from 0.1 to 10 μM. 2'-Acetylacteoside shows antiproliferative effects on aortic smooth muscle, indicates that it may ha

Zenarestat (CI-1014, FK-366, FR-74366) is an aldose reductase inhibitor being studied as a treatment for diabetic neuropathy and cataracts.

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.

ALR2-IN-2, a potent aldose reductase (ALR2) inhibitor, exhibits IC50 values of 27 nM for rat ALR2 and 228 nM for ALR1, respectively. This compound is utilized in the research of diabetic complications.

ALR1 2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) inhibitor (IC50: 3.26 μM) and aldose reductase (ALR2) inhibitor (IC50: 3.06 μM) with anticancer effects.

Isorhamnetin-3-O-glucoside (Isorhamnetin-3-O-beta-D-Glucoside) inhibits the activity of alpha-glucosidase from rat intestine; it exhibits a potent rat lens aldose reductase (RLAR) inhibition in vitro, its IC(50) being 1.4 microM and has inhibitory effects of sorbitol accumulation, suggests that it is a leading compound for further study as a new drug for the prevention and or treatment of diabetes and its complications.

Poliumoside is a natural compound which exhibits significant inhibition of advanced glycation end product formation with IC50 value of 4.6-25.7 μM, it also exhibits great inhibitory effects on rat lens aldose reductase with IC50 values of 0.85 μM.Poliumos

(Rac)-Byakangelicin (7H-Furo[3,2-g][1]benzopyran-7-one, 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-) is an antineoplastic agent.

M 16287 is a potent aldose reductase inhibitor.

CP-744809 is a highly selective oral small-molecule aldose reductase inhibitor.